home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 -0.56 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday ↗

June 30, 2023

Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...

Via Benzinga

3 Biotech Stocks to Buy With Explosive Upside Potential ↗

June 22, 2023

These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.

Via InvestorPlace

NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed ↗

June 20, 2023

San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of...

Via SBWire

What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

June 14, 2023

Via Benzinga

3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.

Via InvestorPlace

Death Cross Looms Over Biomarin Pharmaceutical Investors ↗

May 02, 2023

Via Benzinga

What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

April 27, 2023

Via Benzinga

A Preview Of Biomarin Pharmaceutical's Earnings ↗

April 25, 2023

Via Benzinga

Where Biomarin Pharmaceutical Stands With Analysts ↗

March 21, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 26, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 25, 2023

Via Benzinga

3 Biotech Stocks With Blockbuster Potential ↗

May 24, 2023

Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.

Via InvestorPlace

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals ↗

May 17, 2023

The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 20, 2023

Via Benzinga

Preview: Biomarin Pharmaceutical's Earnings ↗

February 24, 2023

Via Benzinga

Analyst Ratings for Biomarin Pharmaceutical ↗

February 22, 2023

Via Benzinga

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

BioMarin Pharmaceutical Stock Shows Rising Relative Strength ↗

March 30, 2023

BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.

Via Investor's Business Daily

3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize ↗

March 28, 2023

The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story.

Via The Motley Fool

BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74 ↗

March 21, 2023

A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue?

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Why did Sarepta Therapeutics Stock Plummet?

March 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Via MarketBeat

After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use ↗

March 08, 2023

Via Benzinga

Why BioMarin Shares Are Plunging Today? ↗

March 06, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating ↗

March 03, 2023

On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.

Via Investor's Business Daily

uniQure Stock Trying To Close In On Key Technical Measure ↗

February 28, 2023

uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.

Via Investor's Business Daily

BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023 ↗

February 28, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023 ↗

February 22, 2023

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com